Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) dropped 2.8% during mid-day trading on Tuesday . The company traded as low as $61.70 and last traded at $62.04. Approximately 200,522 shares changed hands during mid-day trading, an increase of 6% from the average daily volume of 189,291 shares. The stock had previously closed at $63.82.
Gemini Therapeutics Stock Performance
The company’s 50 day simple moving average is $62.50 and its 200 day simple moving average is $52.53. The stock has a market cap of $2.71 billion, a PE ratio of -62.54 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- What is the Nasdaq? Complete Overview with History
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Conference Calls and Individual Investors
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is a buyback in stocks? A comprehensive guide for investors
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
